Trial reportDrug and alcohol dependence2013
Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.
Trial report in Drug and alcohol dependence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00790569 (Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers), which is not on this map. Cited by 44 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Who cites it
44 citing papers in PubMed, 10 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Addressing tobacco use in the context of opioid use disorder: A systematic review of smoking cessation interventions.The American journal on addictions · 2026Pooled it
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Nicotine replacement therapy versus control for smoking cessation.The Cochrane database of systematic reviews · 2018Pooled it
- Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.The Cochrane database of systematic reviews · 2016Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- A Systematic Review of Smoking Cessation Interventions for Adults in Substance Abuse Treatment or Recovery.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Pooled it
- Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Pooled it
- Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Timing of smoking cessation treatment integrated into outpatient treatment with medications for opioid use disorder: Feasibility trial.Journal of substance abuse treatment · 2022Trial
- Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.Journal of substance abuse treatment · 2021Trial
- The impact of menthol cigarette use on quit attempts and abstinence among smokers with opioid use disorder.Addictive behaviors · 2021Trial
- Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial.Addiction (Abingdon, England) · 2021Trial
- Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.Journal of substance abuse treatment · 2019Trial
- Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Trial
- Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms.Addiction (Abingdon, England) · 2017Trial
- Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.Psychopharmacology · 2017Trial
- Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence.The American journal on addictions · 2016Trial
- Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment.Drug and alcohol dependence · 2016Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWith smoking rates far exceeding the general population, methadone-maintained (MMT) opiate-dependent smokers experience high rates of tobacco-related health consequences. Previous treatment studies have used nicotine replacement and produced low quit rates.
methodsWe test, using a three-group randomized design, the efficacy of varenicline versus placebo, in comparison with nicotine replacement therapy (NRT) that combines nicotine patch prescription plus ad libitum nicotine rescue, for smoking cessation. We recruited methadone-maintained smokers from nine treatment centers in southern New England and provided six months of treatment, and a minimal behavioral intervention at baseline (NCI's 5A's). Outcomes included carbon monoxide (CO) confirmed 7-day point smoking cessation prevalence at 6 months and self-reported change in mean cigarettes per day.
resultsThe 315 participants had a mean age of 40, with 50% male and 79% non-Hispanic White, smoked an average of 19.6 (± 10.4) cigarettes/day, and had a mean daily methadone dose of 109 mg. Intent-to-treat analyses, with missing considered to be smoking, showed the rate of CO-confirmed 7-day abstinence at 6-months was 5.4% overall, with varenicline 3.7% compared to placebo 2.2%, and NRT 8.3% (p>.05). Adherence rates during the 7-days immediately prior to 6-month assessment were 34.2% in varenicline, 34.4% in placebo, and 48.8% in NRT. Between baseline and 6-months there was an overall self-reported mean reduction of 8.3 cigarettes/day.
conclusionVarenicline did not increase quit rates over placebo. Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.